Endotracheal Tubes Coated With A Broad-Spectrum Antibacterial Ceragenin Reduce Bacterial Biofilm In An In Vitro Bench Top Model

Background: Ventilator-associated pneumonia is one of the most common nosocomial infections, caused mainly by bacterial/fungal biofilm. Therefore, it is necessary to develop preventive strategies to avoid biofilm formation based on new compounds.Objectives: We performed an in vitro study to compare the efficacy of endotracheal tubes (ETTs) coated with the ceragenin CSA-131 and that of uncoated ETTs against the biofilm of clinical strains of Pseudomonas aeruginosa (PA), Escherichia coli (EC) and Staphylococcus aureus (SA).Methods: We applied an in vitro bench top model using coated and uncoated ETTs that were treated with three different clinical strains of PA, EC and SA for 5days. After exposure to biofilm, ETTs were analysed for cfu count by culture of sonicate and total number of cells by confocal laser scanning microscopy.Results: The median (IQR) cfu/mL counts of PA, EC and SA in coated and uncoated ETTs were, respectively, as follows: 1.00x10(1) (0.0-3.3x10(2)) versus 3.32x10(9) (6.6x10(8)-3.8x10(9)), P<0.001; 0.0 (0.0-5.4x10(3)) versus 1.32x10(6) (2.3x10(3)-5.0x10(7)), P<0.001; and 8.1x10(5) (8.5x10(1)-1.4x10(9)) versus 2.7x10(8) (8.6x10(6)-1.6x10(11)), P=0.058. The median (IQR) total number of cells of PA, EC and SA in coated and non-coated ETTs were, respectively, as follows: 11.0 [5.5-not applicable (NA)] versus 87.9 (60.5-NA), P=0.05; 9.1 (6.7-NA) versus 62.6 (42.0-NA), P=0.05; and 97.7 (94.6-NA) versus 187.3 (43.9-NA), P=0.827.Conclusions: We demonstrated significantly reduced biofilm formation in coated ETTs. However, the difference for SA was not statistically significant. Future clinical studies are needed to support our findings.